Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Shapiro

Showing results (781-790 of 1,171) with videos related to

Pageof 118
Sort By:
Investigational New Drugs|June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumorsJames M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
Protein Engineering, Design & Selection : PEDS|February 10, 2017
Engineering potent long-acting variants of the Wnt inhibitor DKK2Richelle Sopko, Joshua W Mugford, Andreas Lehmann, et al.
Shock (Augusta, Ga.)|January 12, 2016
Assessing The Predictive Value of Clinical Factors Used to Determine The Presence of Sepsis Causing Shock in the Emergency DepartmentDaniel J Henning, Jeremy R Carey, Kimie Oedorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2016
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and LymphomasJeffrey R Infante, Philippe A Cassier, John F Gerecitano, et al.
Journal of the American College of Cardiology|December 15, 2015
Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure GradientTimothy P Murphy, Christopher J Cooper, Alan H Matsumoto, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case reportDouglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, et al.
Science (New York, N.Y.)|December 6, 1974
Transcontinental baselines and the rotation of the Earth measured by radio interferometryI I Shapiro, D S Robertson, C A Knight, et al.
Science (New York, N.Y.)|January 7, 1983
Detection of a Compact Radio Source near the Center of a Gravitational Lens: Quasar Image or Galactic Core?M V Gorenstein, I I Shapiro, N L Cohen, et al.
International Journal of Molecular Sciences|July 9, 2022
Tumor-Suppressor Role of the α1-Na/K-ATPase Signalosome in NASH Related Hepatocellular CarcinomaUtibe-Abasi S Udoh, Moumita Banerjee, Pradeep K Rajan, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 9, 2011
Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4Renée I Shapiro, Tatiana Plavina, Brian R Schlain, et al.
Pageof 118

Showing results (781-790 of 1,171) with videos related to

Sort By:
Pageof 118
Investigational New Drugs|June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumorsJames M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
Protein Engineering, Design & Selection : PEDS|February 10, 2017
Engineering potent long-acting variants of the Wnt inhibitor DKK2Richelle Sopko, Joshua W Mugford, Andreas Lehmann, et al.
Shock (Augusta, Ga.)|January 12, 2016
Assessing The Predictive Value of Clinical Factors Used to Determine The Presence of Sepsis Causing Shock in the Emergency DepartmentDaniel J Henning, Jeremy R Carey, Kimie Oedorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2016
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and LymphomasJeffrey R Infante, Philippe A Cassier, John F Gerecitano, et al.
Journal of the American College of Cardiology|December 15, 2015
Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure GradientTimothy P Murphy, Christopher J Cooper, Alan H Matsumoto, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case reportDouglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, et al.
Science (New York, N.Y.)|December 6, 1974
Transcontinental baselines and the rotation of the Earth measured by radio interferometryI I Shapiro, D S Robertson, C A Knight, et al.
Science (New York, N.Y.)|January 7, 1983
Detection of a Compact Radio Source near the Center of a Gravitational Lens: Quasar Image or Galactic Core?M V Gorenstein, I I Shapiro, N L Cohen, et al.
International Journal of Molecular Sciences|July 9, 2022
Tumor-Suppressor Role of the α1-Na/K-ATPase Signalosome in NASH Related Hepatocellular CarcinomaUtibe-Abasi S Udoh, Moumita Banerjee, Pradeep K Rajan, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 9, 2011
Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4Renée I Shapiro, Tatiana Plavina, Brian R Schlain, et al.
Pageof 118